Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Connect with a weight loss healthcare provider through Klinic to receive a prescription
Abstract Introduction In the head-to-head trial (SUSTAIN 7), the novel, injectable, once-weekly GLP-1 analogue semaglutide showed superiority in both glycemic outcomes and body weight reduction, compared with once-weekly dulaglutide in the treatment of type 2 diabetes (T2D)
Adult only
Diet-induced obesity (DIO) mice were generated by starting a high-fat diet (HFD-60, lipid 60 kcal%, Oriental Yeast) feeding for C57B6J (B6) mice (Oriental Yeast) at six weeks of age
:max_bytes(150000):strip_icc()/VWH-GettyImages-2196287905-42e440cc5f714dfb8793161a905904d9.jpg)
US$ 22.61
US$ 21.80
US$ 21.29
US$ 22.37
